Results 211 to 220 of about 192,841 (253)

Giant ancient schwannoma of pancreatic head treated by extended pancreatoduodenectomy

Pancreatology, 2004
We report a case of a 55-year-old woman who was transferred from another center to our university clinic after diagnostic laparotomy with a pancreatic head tumor which was seen to encase the portal vein. Although intraoperative biopsies were performed, a histologic diagnosis of the tumor was not possible before giving suspect to a malignant tumor being
Dobschütz, Ernst von, Walch, Axel Karl, Werner, Martin, Hopt, Ulrich T., Adam, Ulrich   +4 more
openaire   +3 more sources

Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial

Japanese Journal of Ophthalmology, 2021
To investigate the efficacy and safety of a treat-and-extend (T&E) regimen using aflibercept (Eylea) for diabetic macular edema (DME).Prospective, open-label, multicenter, single-arm, nonblinded clinical study.Forty eyes of 40 patients with DME received a T&E regimen of intravitreal aflibercept injection (IAI) with the longest treatment interval set to
Takao, Hirano, Yuichi, Toriyama, Yoshihiro, Takamura, Masahiko, Sugimoto, Taiji, Nagaoka, Yoshimi, Sugiura, Fumiki, Okamoto, Michiyuki, Saito, Kousuke, Noda, Shigeo, Yoshida, Akihiro, Ishibazawa, Osamu, Sawada, Toshinori, Murata   +12 more
openaire   +2 more sources

Treat and extend versus PRN in diabetic retinopathy

Acta Ophthalmologica, 2016
SummaryVascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of the neo‐vascular age related macular degeneration (nAMD) and the ischemic retinal microangiopathies. Targeting VEGF in retinal diseases became an effective therapeutic option.To optimize the benefit of risk ratio and cost effectiveness of anti‐VEGF agents, a number
openaire   +1 more source

The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK

Advances in Therapy, 2016
Wet age-related macular degeneration (AMD) is a chronic eye condition that causes severe deterioration of vision and even blindness. Current wet AMD treatment in the UK involves the vascular endothelial growth factor inhibitors ranibizumab and aflibercept.
Wrik, Ghosh, Rose, Wickstead, Lindsay, Claxton, Jeanette, Kusel, Matthew, Taylor, Kelly, Fleetwood, Ruth, Pulikottil-Jacob   +6 more
openaire   +2 more sources

Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy

British Journal of Ophthalmology, 2018
AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour, Abdulrazzak, Charbaji, Michel Eid, Farah, Hana A, Mansour, Jay, Chhablani   +4 more
openaire   +2 more sources

Treat and extend regimen for diabetic macular oedema—a systematic review and meta-analysis

Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
Various treatment regimens are currently practiced in the treatment of CI-DMO (centre-involving diabetic macular oedema). In recent years, there has been a growing body of evidence supporting a treat and extend (T&E) regimen for DMO which offers the promise of comparable visual and anatomical outcomes while reducing injection burden. This meta-analysis
Sheng Yang Lim, Wendy Meihua Wong, Ivan Seah, Hwei Wuen Chan, Xinyi Su, Gopal Lingam, Yew Sen Yuen   +6 more
openaire   +2 more sources

Hydrosalpinx treated with extended doxycycline does not compromise the success of in vitro fertilization

Fertility and Sterility, 2001
To determine if extended treatment with doxycycline before and after an in vitro fertilization (IVF) procedure can minimize the detrimental effect of a hydrosalpinx.Retrospective analysis.University IVF program.Patients undergoing IVF, including 17 with a hydrosalpinx, 25 with adhesions or proximal tubal occlusion, and 22 with endometriosis or ...
B S, Hurst, K E, Tucker, C A, Awoniyi, W D, Schlaff   +3 more
openaire   +2 more sources

TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY

Retina, 2017
To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV).We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose ≥3 best-corrected visual acuity (BCVA ...
Kang Yeun, Pak, Sung Who, Park, Ik Soo, Byon, Ji Eun, Lee   +3 more
openaire   +2 more sources

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

Graefe's Archive for Clinical and Experimental Ophthalmology, 2017
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve polypoidal choroidal vasculopathy (PCV).In a retrospective interventional case series of 58 eyes of 58 patients with PCV, we assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and number of ...
Dan, Călugăru, Mihai, Călugăru
openaire   +4 more sources

Treat and extend protocol outcomes in diabetic macular edema: A narrative review

American Journal of Ophthalmic Clinical Trials, 2022
The objective of this study was to pool available data on change in visual acuity, number of injections, and change in central subfield thickness as reported by treat and extend (T&E) regimens for diabetic macular edema (DME) compared to monthly and pro re nata (PRN) regimens.
Param Bhatter, Abhinav Bheemidi, Justin C. Muste, Shirley Z. Wu, Molly J. E. Snider, Carolina C. S. Valentim, Rishi P. Singh   +6 more
openaire   +1 more source